ElhamyDaoudEskanderMDFACP

Oncology • Frederick, MD

Hematologic Oncology

Physician

Join to view full profile

Dr. Eskander is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Eskander's full profile

Already have an account?

Office
501 W 7th St
Suite 1a
Frederick, MD 21701
Phone+1 301-662-8477

Fax+1 301-662-4293

Education & Training

Penn State Milton S Hershey Medical CenterFellowship, Hematology and Medical Oncology, 1992 - 1995
Conemaugh Memorial Medical CenterResidency, Internal Medicine, 1988 - 1991
UPMC Medical EducationResidency, Pathology-Anatomic and Clinical, 1986 - 1988
Cairo University School of MedicineClass of 1979

Certifications & Licensure

MD State Medical License 1995 - 2026
PA State Medical License 1987 - 2000
GA State Medical License 1995 - 1997
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Start of enrollment: 2009 Jul 16
Completed
Phase 2
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

18 citations
Phase I study combining tumor necrosis factor with interferon-α and interleukin-2
Elhamy D. Eskander, Harold A. Harvey, Elise Givant, Allan Lipton
American Journal of Clinical Oncology. 1997-10-01